The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•28 April 2026•

1 min read

Idorsia’s QUVIVIQ Sales Surge 74% in Q1 2026 Financial Results

Key Facts

1Idorsia reported a 74% year-on-year sales growth for its drug QUVIVIQ in the first quarter of 2026.

2Partnering discussions for TRYVIO and JERAYGO are ongoing with several parties.

3Preparation is underway to publish pediatric daridorexant data and engage with regulatory authorities.

Idorsia Ltd has reported its financial results for the first quarter of 2026, highlighted by a robust 74% year-on-year surge in sales for its drug QUVIVIQ. This significant growth was primarily driven by expanded co-promotion efforts across key European markets. Alongside the sales performance, the company confirmed that partnering discussions for its assets TRYVIO and JERAYGO are currently ongoing with multiple parties. Furthermore, Idorsia is preparing to publish strong pediatric data for daridorexant and engage with regulatory authorities for next steps. These developments underscore a positive commercial trajectory and progress in the company’s clinical pipeline. Investors remain focused on the potential conclusion of partnership deals to further bolster the company's financial position.